摘要
目的:研究增殖细胞相关抗原(Ki67)在甲状腺髓样癌中的表达及临床意义。方法:采用免疫组化SP法检测42例甲状腺髓样癌组织、18例癌旁组织中Ki67的表达,并分析Ki67增殖指数与临床病理学指标间的关系。结果:42例甲状腺髓样癌组织中Ki67的表达率为85.71%(36/42),明显高于其在癌旁组织中的表达率0%(0/18)(P<0.05)。Ki67增殖指数与患者肿瘤大小、临床分期、淋巴结转移有关(P<0.05),而与患者年龄、性别无关(P>0.05),Ki67的表达水平与患者的生存时间无显著相关性(P=0.2283)。结论:Ki67高表达与甲状腺髓样癌的发生、发展及浸润转移有关,可作为判断甲状腺髓样癌生物学行为的重要指标,但Ki67的表达水平并不能作为判断患者预后的指标。
Objective： To investgate the expression of Ki67 in medullary thyroid carcinoma（ MTC） and its relationship with the clinicopathologic characteristics of patients of MTC. Methods： The expression of Ki67 was studied in42 cases of medullary thyroid carcinoma tissue and 18 cases of adjacent nontumor tissue by SP immunohistochemistry,and the relationship between expression of Ki67 and clinicopathological indices was analyzed. Results： The positive expression of Ki67 in medullary thyroid carcinoma tissue was 85. 71%（ 36 /42）. There was a significant difference between carcinoma and normal thyroid tissue（ P〈0. 05）. The overexpression of Ki67 in medullary thyroid carcinoma had no relationship with gender and age of patients,but had relationship with size of tumor,clinical staging and lymph node metastasis（ P〈0. 05）. There was no significant difference of the survival time between groups with negative and positive Ki67 expression（ P = 0. 2283）. Conclusion： The overexpression of Ki67 may play an important role in carcinogenesis and progression of medullary thyroid carcinoma. It may be as the indication of biological behavior of medullary thyroid carcinoma. But the expression of Ki67 cannot be used as a prognostic index.
出处
《现代肿瘤医学》
CAS
2015年第7期911-913,共3页
Journal of Modern Oncology
关键词
KI67
甲状腺髓样癌
免疫组化
Ki67
medullary thyroid carcinoma
immunohistochemistry
